EHC

10x Genomics TXG delivered a loss per share of 10 cents in first-quarter 2026, narrower than the year-earlier loss per share of 36 cents. The figure surpassed the Zacks Consensus Estimate by 65.5%. TXG registered revenues of $150.8 million in the first quarter of 2026, which decreased about 2.6% year over year. Excluding $16.8 million related to one-time license and royalty revenue in the first quarter of 2025, revenues increased 9% year over year. However, the figure surpassed the Zacks Consensus Estimate by 3.57%. The company reports revenue under two primary segments: Products and Services and License and royalty revenue. Products and Services revenue totaled $149.9 million, up approximately 8.8% year over year. Within this segment, Total instruments revenues totaled $11.3 million, down 23.9% year over year. In contrast, Total consumables revenues were $129.8 million, representing a 12.5% year-over-year increase. Services revenue totaled $8.8 million, up 15.4% year over year. Meanwhile, License and royalty revenue was $0.9 million compared with $17.1 million in the prior-year quarter, which included $16.8 million related to one-time license and royalty revenue. Geographically, 10x Genomics derives revenues from three major regions: the Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific. In the first quarter of 2026, Total Americas’ revenues were $80.1 million, reflecting a 11.6% year-over-year decline. EMEA revenues totaled $36.9 million, up approximately 15.5% year over year. Meanwhile, Total Asia-Pacific revenues were $33.9 million, representing 4.4% year-over-year growth. 10x Genomics price-consensus-eps-surprise-chart | 10x Genomics Quote In the quarter under review, TXG’s gross profit improved 0.7% year over year to $106.2 million. The gross margin expanded 220 basis points (bps) to 70.3%. Selling, general and administrative expenses fell 26% year over year to $66.4 million. Research and development expenses declined 11.5% year over year to $56.8 million. Total operating expenses of $123.2 million decreased 14.9% year over year. Total operating loss was $17 million, reflecting an improvement from the prior-year loss of $39.3 million. TXG exited the first quarter of 2026 with cash, cash equivalents and marketable securities of $539.8 million, up from $523.4 million at the end of the fourth quarter of 2025. Importantly, the company e...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 12 cents in first-quarter 2026, narrower than the year-ago adjusted loss of 15 cents per share. The adjusted loss per share topped the Zacks Consensus Estimate by 29.4%. The company’s GAAP loss per share was 3 cents in the quarter compared with the year-ago period’s loss of $1.44. PacBio registered total revenues of $37.2 million in the first quarter, flat year over year. The figure missed the Zacks Consensus Estimate by 9.3%. Shares of the company lost around 4% in yesterday’s trading session. PacBio’s revenues from the Americas were $16.7 million, up 2%year over year. In the Asia-Pacific region, PacBio recorded revenues of $9.7 million, reflecting a 16% decrease year over year. The Europe, the Middle East and Africa (EMEA) region registered revenues of $10.8 million, which improved 17% year over year. Total Product revenues amounted to $31.5 million, up 1.4% from the year-ago quarter. Within the Product segment, Instrument revenues were $9.7 million, down 12% year over year.Instrument revenues in the first quarter of 2026 included 15 Revio sequencing systems and 27 Vega sequencing systems. PACB ended the quarter with 346 cumulative Revio system shipments and 174 cumulative Vega system shipments. Consumables revenues for the first quarter of 2026 were $21.8 million, up 9% from the prior-year quarter. AnnualizedRevio pull-through per system was $229,000 in the quarter. Service and other revenues totaled $5.6million, down 6.6% year over year. Pacific Biosciences of California, Inc. price-consensus-eps-surprise-chart | Pacific Biosciences of California, Inc. Quote In the quarter under review, PacBio’s adjusted gross profit decreased 8% year over year to $13.8 million. The adjusted gross margin contracted 300 basis points to 37%. Sales, general and administrative expenses declined 22.5% year over year to $31.2 million. Research and development expenses decreased 32.5% year over year to $19.6 million. Adjusted total operating expenses of $49.9 million decreased 19.1% year over year. Total operating loss was $8.4 million in the reported quarter compared with the prior-year quarter’s $428.9 million. PacBio exited the first quarter of 2026 with cash and investmentsof $275.9million compared with $279.5million at the end of the fourth quarter of 2025. PacB...

Solventum SOLV reported first-quarter 2026 adjusted earnings per share (EPS) of $1.48, which beat the Zacks Consensus Estimate of $1.35 by 9.6%. The bottom line improved 10.4% year over year. GAAP EPS in the quarter was 7 cents compared with 78 cents in the year-ago quarter. The company reported revenues of $2 billion, down 3% reportedly from the prior-year recorded number. Organically, sales were up 2.1%. The metric beat the Zacks Consensus Estimate by 1%. Organic sales growth was driven by positive performance from all segments, primarily driven by results of the Infection Prevention and Surgical Solutions business within MedSurg, as well as Dental Solutions. However, shares of the company were down 2.8% during after-hours trading on May 5. MedSurg Revenues from the segment totaled $1.2 billion, up 1.2% organically year over year. Growth was driven by continued strength in Advanced Wound Care, where Negative Pressure Wound Therapy benefited from strong brand momentum, new product launches and commercial enhancements. Management also highlighted ongoing demand for traditional and single-use therapies, including V.A.C. Peel and Place Dressings, alongside contributions from the recently acquired Acera business. Infection Prevention & Surgical Solutions delivered solid performance despite a tough year-ago comparison, supported by improved commercial alignment, healthy customer demand and continued traction for Tegaderm CHG and recent Attest sterilization product launches. Dental Solutions Segment revenues totaled $354 million, up 3.4% organically year over year. Growth was primarily driven by strong demand in core restoratives, supported by new product launches such as Filtek Easy Match and Clinpro Clear, along with benefits from a more specialized sales force. Management also noted continued progress in reducing backorders, which improved customer service levels and supported momentum across the business. Health Information Systems (HIS) Revenues from the segment were $342 million, up 4.7% organically year over year. Growth was driven by continued strength in Revenue Cycle Management and Performance Management solutions, particularly within autonomous coding offerings across inpatient and outpatient settings. The company also benefited from strong customer retention, backlog conversion and ongoing international expansion, partially offset by expected double-d...

QuidelOrtho Corporation QDEL delivered adjusted loss per share of 4 cents in first-quarter 2026 against earnings per share (EPS) of 74 cents in the prior-year quarter. The figure missed the Zacks Consensus Estimate by 110.8%. The adjustments include expenses related to the amortization of intangibles, acquisition and integration costs, among others. GAAP loss per share for the quarter was $1.35 compared with the year-earlier loss of 19 cents. QuidelOrtho registered revenues of $619.8 million in the first quarter of 2026, which decreased 10.5% year over year on a reported basis and 12.6% at constant exchange rate (CER). However, the figure surpassed the Zacks Consensus Estimate by 0.3%. In the first quarter, Respiratory revenues were $67.9 million (down 43.3% on a reported basis and 43.6% at CER), while Non-Respiratory revenues were $551.9 million (down 3.7% on a reported basis and 6.2% at CER). Shares of the company lost around 6% in yesterday’s trading session. QuidelOrtho derives revenues from five business units — Labs, Immunohematology, Donor Screening, Point of Care and Molecular Diagnostics. As a result of the wind-down of the U.S. Donor Screening portfolio, the previously reported Transfusion Medicine business unit is now presented in its two product categories — Immunohematology and Donor Screening. In the first quarter, Labs revenues were $353.1 million, down 5.3% on a reported basis and 7.6% at CER. Immunohematologyrevenues were $138.3 million in the first quarter, up 7.6% and 3.4% on a reported basis and at CER, respectively. Donor Screening revenues were $7.8 million in the first quarter, down 39.1% and 39.5% on a reported basis and at CER, respectively. Point of Care revenues amounted to $112.8 million in the first quarter, reflecting a decline of 35%on a reported basis and 34.6% at CER. Molecular Diagnosticsrevenues totaled $7.8million in the first quarter, up 2.6% and down 1.8% on a reported basis and at CER, respectively. Geographically, QuidelOrtho derives revenues from North America, Europe, the Middle East and Africa (EMEA), China, Latin America and Japan and other Asia-Pacific markets (JPAC). Revenues from North Americaamounted to $328.9million, reflecting a decline of 19.1% on a reported basis and 18.9% at CER. EMEA revenues amounted to $92.5million, reflecting an increase of 4% on a reported basis and a decline of 6.1% at CER. Revenues...

Encompass Health Corporation recently reported first-quarter 2026 results showing revenue of US$1,586.6 million and net income of US$194.5 million, with both basic and diluted earnings per share from continuing operations higher than a year earlier. Alongside this earnings improvement, the company continued to return capital through share repurchases and deepened its presence in Tennessee via a new Cookeville rehabilitation hospital partnership, underscoring its focus on inpatient rehabilitation capacity and service breadth. We’ll now examine how this earnings uptick, combined with ongoing share buybacks, interacts with Encompass Health’s existing investment narrative and outlook. The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation. To own Encompass Health, you need to be comfortable with a capital intensive, inpatient rehab model that leans on aging demographics and complex-care demand while managing labor and reimbursement pressure. The latest quarter’s higher revenue and earnings, alongside continued buybacks, support this capacity led story but do not meaningfully change the near term swing factor, which still looks tied to execution on new hospital openings versus rising wage and construction cost risk. The new Cookeville Regional Medical Center partnership fits cleanly into this thesis, adding future beds and reinforcing Encompass Health’s focus on complex neurological and stroke rehabilitation in an underserved Tennessee market. As with other recent de novo projects, it highlights how growth in medically complex admissions can be a key earnings driver while also amplifying exposure to capital expenditure overruns and ramp up uncertainty. Yet investors should also weigh how rising build out and labor costs could pressure margins just as this expansion phase gathers pace and... Read the full narrative on Encompass Health (it's free!) Encompass Health's narrative projects $7.4 billion revenue and $769.8 million earnings by 2029. Uncover how Encompass Health's forecasts yield a $142.73 fair value, a 36% upside to its current price. Four members of the Simply Wall St Community currently see Encompass Health’s fair value between US$99.17 and US$167.49 per share, highlighting very different expectations. You can set those views against the company’s ongoing, c...

iRhythm Holdings, Inc. IRTC reported an adjusted loss per share of 35 cents in the first quarter of 2026 compared with an adjusted loss of 95 cents in the year-ago period. The figure was 37.5% narrower than the Zacks Consensus Estimate. GAAP loss per share for the quarter was 43 cents compared with 97 cents in the year-ago period. iRhythm registered revenues of $199.4 million in the first quarter, up 25.7% year over year. The increase was primarily driven by sustained volume demand across the customer base, reflecting continued strength in the core business and contributions from newer growth channels. The figure surpassed the Zacks Consensus Estimate by 2.9%. Shares of IRTC were up approximately 7% during after-market trading following the first-quarter results. However, the company’s shares have declined 31.9% in the year-to-date period compared with the industry’s loss of 19.1%. The broader S&P 500 Index has increased 6.5% in the same time frame. Image Source: Zacks Investment Research iRhythm derives revenues from the following sources: Contracted third-party payors, Centers for Medicare & Medicaid Services, Healthcare institutions and Non-contracted third-party payors. In the first quarter of 2026, the Contracted third-party payors revenues totaled $106.8 million, up 27.4% year over year. The Healthcare institutions revenues totaled $51.4 million, up 34.8% year over year. The Centers for Medicare & Medicaid Services revenues totaled $30.2 million, up 13% year over year. The Non-contracted third-party payors revenues totaled $11 million, up 9.4% year over year. In the quarter under review, iRhythm’s gross profit rose 29.4% year over year to $141.4 million. The gross margin expanded 210 basis points (bps) to 70.9%. Selling, general and administrative expenses increased 13.3% year over year to $135.9 million, and research and development expenses decreased 0.7% year over year to $21.4 million. Adjusted operating expenses of $153.5 million rose 9.3% year over year. The operating loss totaled $16.2 million, down from $32.6 million in the prior-year quarter. iRhythm exited first-quarter 2026 with cash and cash equivalents of $240.1 million compared with $236 million at the end of fourth-quarter 2025. Cumulative net cash used in operating activities at the end of first-quarter 2026 was $26.2 million compared with $7.9 million a year ago. iRhythm has increased...

STERIS plc STE is scheduled to release fourth-quarter fiscal 2026 results on May 12, after market close. In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.53, which matched the Zacks Consensus Estimate. STE’s earnings beat estimates in three of the trailing four quarters and met once, delivering an average surprise of 2.61%. The Zacks Consensus Estimate for revenues is pegged at $1.60 billion, implying an increase of 7.9% from the year-ago reported figure. The same for EPS is pegged at $2.89, indicating a year-over-year increase of 5.5%. Estimates for earnings have remained constant at $2.89 per share in the past 30 days. Let's take a look at how things might have shaped up for the MedTech major prior to the announcement. Healthcare In the previous quarter, growth across all categories was robust. We expect this trend to have continued in the fiscal fourth quarter as well. The company maintains confidence in recurring revenue streams and backlog strength. This should get reflected in the fiscal fourth-quarter results. Also, in the to-be-reported quarter, capital equipment growth is expected to have remained robust. Per the Zacks Consensus Estimate, the segment’s revenues are expected to improve 7.5% from the year-ago reported figure. Applied Sterilization Technologies In the fiscal fourth quarter, Steris is expected to have experienced organic revenue growth within this segment. Also, service revenues are likely to have benefited from stable medical device volumes, bioprocessing demand and favorable currency. Per the Zacks Consensus Estimate, the Applied Sterilization Technologies (“AST”) segment’s revenues are likely to increase 7.9% year over year. STERIS plc price-eps-surprise | STERIS plc Quote Life Sciences The segment's fiscal third-quarter 2025 revenues rose year over year due to strong growth in consumables revenues. The company also experienced a return of capital equipment shipments. These trends might have continued in the to-be-reported quarter. Per the Zacks Consensus Estimate, the segment’s revenues are expected to increase 10.8% year over year. Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating on earnings, which is not the case here. Earnings ESP: STERIS has an Earnings ESP of 0.00%. You can uncover the...

BrightSpring Health Services, Inc. BTSG reported first-quarter 2026 adjusted earnings per share (EPS) of 39 cents, which beat the Zacks Consensus Estimate of 29 cents by 34.5%. The bottom line improved 105.3% year over year. GAAP EPS in the quarter was 34 cents compared with 5 cents in the year-ago quarter. The company reported revenues of $3.61 billion, up 25.6% from the prior-year recorded number. The metric beat the Zacks Consensus Estimate by 8.35%. Revenue growth was fueled by positive performance from all segments, primarily driven by results of the Specialty and Infusion business within Pharmacy Solutions, as well as the Home Healthcare business within the Provider Services segment. Shares of BTSG were up approximately 10% during after-market trading following the first-quarter results. However, the company’s shares have climbed 40.4% in the year-to-date period against the industry’s decline of 11.6%. The broader S&P 500 Index has increased 6.5% in the same time frame. Image Source: Zacks Investment Research Pharmacy Solutions Revenues from this segment totaled $3.17 billion, up 25.2% reportedly year over year. The sales growth was fueled by strong performance in Specialty and Infusion, which was driven by strength in specialty and market adoption of existing LDDs, new LDD wins, brand-to-generic conversions and generic utilization and growth in fee-for-service programs, including hubs and service agreements and strong commercial execution. Infusion contributed through solid volume growth and operational metrics driven by process improvements. However, Home and Community Pharmacy revenues represented a decline due to the impact of the IRA. Provider Services Revenues totaled $442 million, up 27.9% year over year. Growth was driven primarily by strong Home Healthcare growth supported by census growth, de novo expansion, preferred MA contracts and ongoing successful integration of acquired branches. Gross profit was $482.2 million, up 42.5% year over year. As a percentage of revenues, the gross margin was 15.2%, up 180 bps from the prior-year quarter’s figure. Selling, general and administrative expenses totaled $360.8 million, up 25.4% year over year. Operating income totaled $121.4 million, up 139.4% year over year. As a percentage of revenues, the operating margin was 3.8%, up 180 bps from the prior-year quarter’s figure. BrightSpring exited the first...

This article first appeared on GuruFocus. Revenue: Increased 9% to $1.59 billion. Adjusted EBITDA: Increased 11.2% to $348.8 million. Discharge Growth: 4.3% overall growth, including 1.6% same-store discharge growth. Net Revenue per Discharge: Increased by 3.7%. Bad Debt Expense: Increased 20 basis points to 2.2%. RN Turnover: Decreased to 17.8% from 20.2% in the previous year. Therapist Turnover: Decreased to 6.4% from 7.8% in the previous year. Premium Labor Spend: Declined 9.4% compared to Q1 2025. Free Cash Flow: Adjusted free cash flow was $194 million. Share Repurchase: Approximately 708,000 shares repurchased for $71.6 million. Cash Dividend: Paid $0.19 per share and declared another $0.19 per share dividend. Net Leverage: 1.9x at quarter end. 2026 Guidance: Raised to $6.375 billion to $6.470 billion in net operating revenue, $1.35 billion to $1.38 billion in adjusted EBITDA, and $5.89 to $6.11 in adjusted earnings per share. Warning! GuruFocus has detected 7 Warning Sign with NPKI. Is EHC fairly valued? Test your thesis with our free DCF calculator. Release Date: May 01, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Encompass Health Corp (NYSE:EHC) reported a 9% increase in first-quarter revenue and an 11.2% rise in adjusted EBITDA, leading to an upward revision of their 2026 guidance. The company achieved significant improvements in patient outcomes, with discharge community rates improving by 50 basis points to 84.5%, exceeding industry averages. EHC has successfully reduced RN turnover to 17.8%, the lowest since 2012, contributing to a 9.4% decline in premium labor spend compared to Q1 2025. The company is expanding its capacity with plans to open 7 new hospitals and add 100 to 150 beds to existing hospitals, addressing strong demand for inpatient rehabilitation services. EHC is actively investing in clinical staff development, which has led to increased participation in career ladder programs and improved staff retention. Bad debt expense increased by 20 basis points to 2.2%, primarily due to writing off claims from 2013 associated with a legacy audit appeal. The closure of certain IRF units impacted total and same-store discharge growth by approximately 85 basis points. Occupancy constraints in certain markets have become a challenge, with 35% of hospitals experiencing occupancy rates a...

Image source: The Motley Fool. Friday, May 1, 2026 at 10 a.m. ET President and Chief Executive Officer — Mark Tarr Chief Financial Officer — Douglas Coltharp Chief Operating Officer — Patrick Tuer Need a quote from a Motley Fool analyst? Email [email protected] Our supplemental information and discussion on this call will include certain non-GAAP financial measures. For such measures, reconciliation to the most directly comparable GAAP measure is available at the end of the supplemental information, at the end of the earnings release and as part of the Form 8-K filed yesterday with the SEC, all of which are available on our website. I would like to remind everyone that we would adhere to the one question and one follow-up question rule to allow everyone to submit a question. If you have additional questions, please feel free to put yourself back in the queue. With that, I'll turn the call over to President and Chief Executive Officer, Mark Tarr. Mark Tarr: Thank you, Mark, and good morning, everyone. We are pleased with our start to 2026 as first quarter revenue increased 9% and adjusted EBITDA increased 11.2%. Based primarily on our Q1 results, we are raising our guidance for 2026. Doug will review the details in his comments. We achieved these strong results while once again delivering outstanding patient outcomes. Compared to Q1 of '25, our discharge community rate improved 50 basis points to 84.5%. Our discharge acute rate improved 30 basis points to 8.6% and our discharge to SNF rate improved 20 basis points to 6.2%. Our performance on each of these quality metrics exceeds the industry average. We continue to invest in our clinical staff by providing professional growth and development programs such as our career ladder programs, providing nurses with support to attain Certified Rehabilitation RN Certifications and offering in-house continuing education opportunities. We've seen increased participation in and benefits from these development programs. We believe our success in these programs contributes to the continuing improvement in our clinical staff turnover trends. Q1 of '26 annualized RN turnover was 17.8%, down from fiscal year '25's 20.2% and annualized therapist turnover was 6.4%, down from last year's 7.8%. This represents our lowest RN turnover rate since at least 2012 and helped drive a 9.4% decline in premium labor spend compared to Q1 of 2025. W...

Encompass Health reported Q1 revenue of $1.59 billion (+9%) and adjusted EBITDA of $348.8 million (+11.2%), and has raised full‑year 2026 guidance to net operating revenue $6.375–$6.470 billion, adjusted EBITDA $1.35–$1.38 billion, and adjusted EPS $5.89–$6.11. Management highlighted improved clinical outcomes and staffing — RN turnover fell to 17.8% (its lowest since at least 2012) and therapist turnover to 6.4% — contributing to a 9.4% decline in premium labor spend, although salary, wages and benefits per FTE rose 3.7% partly due to career‑ladder pay increases. Strong demand and high occupancy (Q1 average 78.7% with ~35% of hospitals >90%) are driving capacity adds — a 49‑bed hospital opened and seven more hospitals (~340 beds) plus 100–150 bed expansions are planned — and the company is piloting a small‑format hospital hub‑and‑spoke strategy while monitoring regulatory changes (TeamWorks, RCD expansion, and a proposed 2.4% 2027 Medicare update) for short‑term impacts. Interested in Encompass Health Corporation? Here are five stocks we like better. More Than Yield: 5 Stocks Beating the Market and Hiking Dividends Encompass Health (NYSE:EHC) reported first-quarter 2026 results that management said reflect strong underlying demand for inpatient rehabilitation facility (IRF) services, improving staffing trends, and continued investment in new capacity. The company also raised its full-year 2026 guidance following the quarter’s performance. President and CEO Mark Tarr said the company was “pleased with our start to 2026,” noting that first-quarter revenue rose 9% and adjusted EBITDA increased 11.2% year over year. CFO Doug Coltharp reported revenue of $1.59 billion and adjusted EBITDA of $348.8 million. → Corning Beats Q1 Estimates but Drops 9% on Guidance Miss Top Analyst-Rated Healthcare Stocks to Watch Now Coltharp said the revenue increase was driven by both volume and pricing: discharge growth of 4.3% (including 1.6% same-store discharge growth) and a 3.7% increase in net revenue per discharge. He attributed net revenue per discharge growth to patient mix and a favorable comparison related to the annual Medicare Supplemental Security Income (SSI) adjustment. Bad debt expense increased 20 basis points to 2.2%, which Coltharp said was “primarily as a result of writing off claims from 2013 associated with a legacy audit appeal.” → Meta Posted Its Best Sales...

Encompass Health (EHC) came out with quarterly earnings of $1.6 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $1.37 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +6.14%. A quarter ago, it was expected that this rehabilitation hospital operator would post earnings of $1.29 per share when it actually produced earnings of $1.46, delivering a surprise of +13.18%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Encompass Health, which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, posted revenues of $1.59 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.93%. This compares to year-ago revenues of $1.46 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Encompass Health shares have lost about 3.3% since the beginning of the year versus the S&P 500's gain of 4.2%. While Encompass Health has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Encompass Health was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see...